Farrant J, Bryant A, Almandoz F, Spickett G, Evans S W, Webster A D
Division of Immunological Medicine, Clinical Research Centre, Harrow, United Kingdom.
Clin Immunol Immunopathol. 1989 May;51(2):196-204. doi: 10.1016/0090-1229(89)90019-6.
We have compared the proliferative responses of an enriched population of B lymphocytes from patients with acquired (common variable) hypogammaglobulinemia (CVH) with the responses of cells from normal individuals. The uptake of [3H]thymidine into DNA was measured on stimulation with a range of interleukins (IL-2, IL-4, and IL-6) and solid-phase anti-IgM. Flow cytometry using CD19 and surface IgM showed that the "non-T" preparations from the peripheral blood of CVH patients either contained B cells within the normal range (30-40% of the cells) or in a minority group no B cells (less than 3% of the cells). Overall, there were no significant differences between the proliferative responses of patients' cells (in the group where normal numbers of B cells were present) and normal cells with any combination of stimulus used. No IgG was produced by cells from any patient and in only one patient was IgM production observed. This suggests that the primary B lymphocyte defect in CVH is in the differentiation phase in B cell function rather than in the growth phase. However, the presence or absence of B cells suggests that different defects exist in subgroups of patients with this disease.
我们比较了获得性（常见变异型）低丙种球蛋白血症（CVH）患者富集的B淋巴细胞群体的增殖反应与正常个体细胞的增殖反应。在用一系列白细胞介素（IL-2、IL-4和IL-6）和固相抗IgM刺激后，测量了[3H]胸腺嘧啶核苷掺入DNA的情况。使用CD19和表面IgM的流式细胞术显示，CVH患者外周血的“非T”制剂要么含有正常范围内的B细胞（占细胞的30-40%），要么在少数群体中不含B细胞（少于细胞的3%）。总体而言，在存在正常数量B细胞的患者组中，患者细胞与正常细胞在使用任何刺激组合时的增殖反应之间没有显著差异。任何患者的细胞均未产生IgG，仅在一名患者中观察到IgM产生。这表明CVH中主要的B淋巴细胞缺陷在于B细胞功能的分化阶段而非生长阶段。然而，B细胞的存在与否表明该疾病患者亚组中存在不同的缺陷。
